NCT00876798已完成3 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 206
- 试验地点
- 89
- 主要终点
- To demonstrate that lixivaptan is safe and effective in achieving and maintaining increased serum sodium concentration in subjects with SIADH and other conditions of euvolemic hyponatremia.
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of oral lixivaptan capsules in subjects with Euvolemic Hyponatremia.
详细描述
Phase I and Phase II clinical trials have demonstrated that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with HF, LCWA, and SIADH. Lixivaptan was previously evaluated in disease states characterized by hyponatremia with euvolemia (SIADH) and hyponatremia combined with fluid overload (HF, LCWA). Lixivaptan demonstrated correction in serum sodium concentration together with marked aquaresis in subjects with hyponatremia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Men or women aged 18 or older.
- •Diagnosis of euvolemic hyponatremia (Na+ < 135 mEq/L).
- •Willing to be observed in a monitored setting for approximately the first 8 hours following treatment initiation (first dose).
- •In the Investigator's judgement the patient has adequate visual and auditory acuity to allow participation in the trial.
排除标准
- •Pregnant or breast-feeding women, or women planning to become pregnant or to breastfeed.
- •Overt symptoms of hyponatremia requiring immediate medical intervention (e.g., coma, seizures).
- •Acute or transient hyponatremia (e.g., associated with head trauma, postoperative state, or use of radiotherapy and/or chemotherapy).
- •Hyponatremia in hypovolemic states (e.g., due to fluid loss through vomiting, diarrhea, burns, etc.). Hypovolemic hyponatremia is defined as the presence of clinical evidence of extracellular fluid volume depletion.
- •Hyponatremia in hypervolemic states (e.g., congestive heart failure). Hypervolemia is defined as a presence of increased total body water with signs of edema.
- •Pseudohyponatremia (i.e., hyponatremia resulting from a laboratory artifact).
- •Hypertonic hyponatremia (e.g., hyponatremia in the setting of hyperglycemia).
- •Hyponatremia as a result of any medication that can safely be withdrawn.
- •Hyponatremia due to hypothyroidism or adrenal insufficiency.
- •Current diagnosis of psychogenic polydipsia.
- •Receiving within 7 days of enrollment other medication for treatment of hyponatremia, specifically: demeclocycline, lithium carbonate, urea, or any vasopressin antagonist.
- •Supine systolic arterial blood pressure of ≤ 90 millimeters of mercury (mmHg).
- •Serum creatinine > 3.0 mg/dL (> 265.2 mol/L).
- •Hypokalemia based on clinical sign/symptoms or lab findings (e.g., serum potassium < 3.5 mEq/L).
- •Uncontrolled diabetes mellitus as defined by the Investigators (e.g., hemoglobin - glycosylated [HbA1c] > 9%).
- •ST-segment elevation myocardial infarction (STEMI) within 30 days or active myocardial ischemia at the time of enrollment.
- •History of cerebral vascular accident (CVA) within 30 days prior to screening.
- •Severe malnutrition in the Investigator's judgment (e.g., body mass index [BMI] < 17).
- •Advanced liver disease or documented diagnosis of cirrhosis or alcoholic hepatitis.
- •Urinary tract obstruction (benign prostatic hypertrophy [BPH] allowed if non-obstructive).
- •History of chronic drug/medication abuse within the past 6 months or current alcohol abuse.
- •Terminally ill or moribund condition with little chance of short-term survival.
- •Receiving vasopressin or its analogs for treatment of any condition.
- •Known allergy to any vasopressin antagonist.
- •Previous participation in a lixivaptan study.
- •Recipient of any investigational treatment within 30 days prior to baseline visit.
- •Unable to take oral medications.
- •Significant neurological disorders (e.g., permanent neurological deficits, probable Alzheimer's disease, normal pressure hydrocephalus, Parkinsonian dementia complex, multi-infarct dementia, mixed dementia, or Huntington's disease).
- •Conditions limiting access to water or an inability to respond to thirst (e.g., hydrophobia, or non-communicative).
研究组 & 干预措施
1
Experimental
Lixivaptan
干预措施: Lixivaptan (Drug)
2
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
To demonstrate that lixivaptan is safe and effective in achieving and maintaining increased serum sodium concentration in subjects with SIADH and other conditions of euvolemic hyponatremia.
时间窗: 6 months
次要结局
- If lixivaptan demonstrates improvement in serum sodium, % of subjects achieving normalized serum sodium, % of subjects requiring fluid restriction, prevention of worsening hyponatremia, and the change from baseline to complete TMT-B.(6 months)
研究者
研究点 (89)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart FailureCongestive Heart FailureNCT01055912CardioKine Inc.170
已完成
不适用
International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430Hyponatremia With Normal Extracellular Fluid VolumeHyponatremia With Excess Extracellular Fluid VolumeNCT01056848CardioKine Inc.135
已完成
3 期
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive DisorderMajor Depressive DisorderNCT03569475Allergan501
已完成
3 期
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderMajor Depressive DisorderNCT00969709Forest Laboratories724
已完成
3 期
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive DisorderMajor Depressive DisorderNCT01377194Forest Laboratories568